Research findings from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, are ...

Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in ...

Schizophrenia is a chronic mental health disorder characterized by hallucinations, delusions, disorganized thinking and ...

Despite tolerability concerns, nomlabofusp's overall efficacy represents a “large win” for Larimar, according to analysts at ...

Research findings from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of ...

Schizophrenia care is shifting. In this article, Dr. Stella Sarraf, founder and CEO of Spinogenix, and Dr. David Walling, ...

Ionis Pharmaceuticals' experimental drug improved walking ability in patients with a rare progressive and often fatal neurological condition, the company said on Monday, meeting the main goal in an ...

See why Scholar Rock Holding Corporation remains a Strong Buy despite regulatory setbacks, with key catalysts ahead and ...

The new therapy is being hailed as a breakthrough. But the small study has some limitations – and hasn’t been peer-reviewed.

ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces that the final results ...

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® ...